Unilateral nigrostriatal 6-hydroxydopamine lesions in mice I: motor impairments identify extent of dopamine depletion at three different lesion sites.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Behavioural Brain Research

• Publication date

  2012-03-01

• Fields of study

  Biology, Medicine, Psychology

• Identifiers
  DOI 10.1016/j.bbr.2011.11.027PMID 22146593
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Longitudinal analysis of the behavioural phenotype in YAC128 (C57BL/6J) Huntington's disease transgenic mice.

  2012cited by this paper
• Unilateral nigrostriatal 6-hydroxydopamine lesions in mice II: predicting l-DOPA-induced dyskinesia.

  2012cited by this paper
• Longitudinal analysis of the behavioural phenotype in R6/1 (C57BL/6J) Huntington's disease transgenic mice.

  2012cited by this paper
• Impact of the lesion procedure on the profiles of motor impairment and molecular responsiveness to L-DOPA in the 6-hydroxydopamine mouse model of Parkinson's disease.

  2011cited by this paper
• Characterisation of behavioural and neurodegenerative changes induced by intranigral 6‐hydroxydopamine lesions in a mouse model of Parkinson’s disease

  2010cited by this paper
• Tests to assess motor phenotype in mice: a user's guide

  2009cited by this paper
• Stepping test in mice: a reliable approach in determining forelimb akinesia in MPTP-induced Parkinsonism.

  2009cited by this paper
• Characterization of the striatal 6-OHDA model of Parkinson's disease in wild type and alpha-synuclein-deleted mice.

  2008cited by this paper
• Moderate degeneration of nigral neurons after repeated but not after single intrastriatal injections of low doses of 6-hydroxydopamine in mice.

  2008cited by this paper
• Characterization of the striatal 6-OHDA model of Parkinson's disease in wild type and α-synuclein-deleted mice

  2008cited by this paper
• Ratings of L‐DOPA‐Induced Dyskinesia in the Unilateral 6‐OHDA Lesion Model of Parkinson's Disease in Rats and Mice

  2007cited by this paper
• Time‐course of nigrostriatal damage, basal ganglia metabolic changes and behavioural alterations following intrastriatal injection of 6‐hydroxydopamine in the rat: new clues from an old model

  2007cited by this paper
• Amphetamine induced rotation in the assessment of lesions and grafts in the unilateral rat model of Parkinson's disease.

  2007cited by this paper
• Use of the narrow beam test in the rat, 6-hydroxydopamine model of Parkinson's disease.

  2007cited by this paper
• Comparison of incremental and accelerating protocols of the rotarod test for the assessment of motor deficits in the 6-OHDA model.

  2006cited by this paper
• Behavioral characterization of a unilateral 6-OHDA-lesion model of Parkinson's disease in mice.

  2005cited by this paper
• Impaired acquisition of skilled behavior in rotarod task by moderate depletion of striatal dopamine in a pre-symptomatic stage model of Parkinson's disease.

  2005cited by this paper
• Comparison of 6-hydroxydopamine-induced medial forebrain bundle and nigrostriatal terminal lesions in a lateralised nose-poking task in rats.

  2005cited by this paper
• The Corridor Task: a simple test of lateralised response selection sensitive to unilateral dopamine deafferentation and graft-derived dopamine replacement in the striatum.

  2005cited by this paper
• Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia.

  2005cited by this paper
• Toxin-induced models of Parkinson’s disease

  2005cited by this paper
• Behavioural profiles of inbred mouse strains used as transgenic backgrounds. I: motor tests

  2004cited by this paper
• Deficits in a lateralized associative learning task in dopamine‐depleted rats with functional recovery by dopamine‐rich transplants

  2004cited by this paper
• Behavioural profiles of inbred mouse strains used as transgenic backgrounds. II: cognitive tests

  2004cited by this paper
• A model of L-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function.

  2004cited by this paper
• Staging of brain pathology related to sporadic Parkinson's disease.

  2003cited by this paper
• Parkinson's Disease Mechanisms and Models

  2003cited by this paper
• The staircase test of skilled reaching in mice.

  2001cited by this paper
• Motor behavioural changes after intracerebroventricular injection of 6-hydroxydopamine in the rat: an animal model of Parkinson's disease.

  2001cited by this paper
• Unilateral striatal dopamine depletion: time‐dependent effects on cortical function and behavioural correlates

  2001cited by this paper
• CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury.

  2000cited by this paper
• Characterization of Progressive Motor Deficits in Mice Transgenic for the Human Huntington’s Disease Mutation

  1999cited by this paper
• Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat.

  1998cited by this paper
• A lateralised grip strength test to evaluate unilateral nigrostriatal lesions in rats.

  1998cited by this paper
• Behavioral and neurochemical dynamics of neurotoxic meso-striatal dopamine lesions.

  1997cited by this paper
• The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments.

  1996cited by this paper
• Forelimb akinesia in the rat Parkinson model: differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test

  1995cited by this paper
• Dopamine-rich grafts in the neostriatum and/or nucleus accumbens: effects on drug-induced behaviours and skilled paw-reaching.

  1993cited by this paper
• The "staircase test": a measure of independent forelimb reaching and grasping abilities in rats.

  1991cited by this paper
• Quantification of lesion-induced dopaminergic supersensitivity using the rotational model in the mouse.

  1985cited by this paper
• Lesion-induced DA supersensitivity in aging C57BL/6J mice.

  1984cited by this paper
• An index of the functional condition of rat sciatic nerve based on measurements made from walking tracks.

  1982cited by this paper
• Effects of preceding sensibilization by reserpine and haloperidol on toxicity of dopaminergic agonists.

  1980cited by this paper
• Circling behavior in rats with partial, unilateral nigro-striatal lesions: effect of amphetamine, apomorphine, and DOPA.

  1980cited by this paper
• Compulsive, abnormal walking caused by anticholinergics in akinetic, 6-hydroxydopamine-treated rats.

  1978cited by this paper
• Mesolimbic dopamine neurons: Effects of 6-hydroxydopamine-induced destruction and receptor blockade on drug-induced rotation of rats

  1977cited by this paper
• The relationship between striatal and mesolimbic dopamine dysfunction and the nature of circling responses following 6-hydroxydopamine and electrolytic lesions of the ascending dopamine systems of rat brain.

  1976cited by this paper
• Unilateral 6-hydroxydopamine lesions of nigrostriatal or mesolimbic dopamine-containing terminals and the drug-induced rotation of rats.

  1975cited by this paper
• Amphetamine and apomorphine responses in the rat following 6-OHDA lesions of the nucleus accumbens septi and corpus striatum.

  1975cited by this paper
• Turning behavior of mice with unilateral 6-hydroxydopamine lesions in the striatum: effects of apomorphine, L-DOPA, amanthadine, amphetamine and other psychomotor stimulants.

  1973cited by this paper
• Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system.

  1970cited by this paper
• 6-Hydroxy-dopamine induced degeneration of central monoamine neurons.

  1968cited by this paper

• Neurofilament light chain protein exposure contributes to protein aggregation, microgliosis, astrogliosis and neuroinflammation via p38/MK2/NF-κB/CREB1/Nrf2/HO-1 signalling leading to Parkinson's disease.

  2026cites this paper
• Phytochemicals against the 6-hydroxydopamine-induced Parkinson’s Phytochemicals against the 6-hydroxydopamine-induced Parkinson’s disease in rodents: a systematic review

  2025cites this paper
• Cortical dopaminergic signaling mediates planning of directional movements

  2025cites this paper
• Early deep brain stimulation attenuates parkinsonism progression in a neurotoxin-induced Parkinson's disease mouse model.

  2025cites this paper
• Modeling neurodegeneration and neuroinflammation in Parkinson's Disease: Animal-based strategies.

  2025cites this paper
• Evaluation of the potential therapeutic effect of africanized honeybee venom (Apis mellifera Linnaeus) on levodopa-induced dyskinesias in mice.

  2025cites this paper
• Apnea behavior in early- and late-stage mouse models of Parkinson's disease: cineradiographic analysis of spontaneous breathing, acute stress, and swallowing.

  2024cites this paper
• Enhancing striatal acetylcholine facilitates dopamine release and striatal output in parkinsonian mice

  2024influential citation
• Subthalamic nucleus deep brain stimulation induces functional deficits in norepinephrinergic neurotransmission in a Parkinson's disease model.

  2024cites this paper
• Neurodegeneration and glial morphological changes are both prevented by TRPM2 inhibition during the progression of a Parkinson's disease mouse model.

  2024cites this paper
• Aqueous extract of Swietenia macrophylla leaf exerts an anti-inflammatory effect in a murine model of Parkinson’s disease induced by 6-OHDA

  2024cites this paper
• Characterization of graded 6-Hydroxydopamine unilateral lesion in medial forebrain bundle of mice

  2024cites this paper
• A mouse model of sleep disorders in Parkinson's disease showing distinct effects of dopamine D2-like receptor activation.

  2023cites this paper
• The role of polyunsaturated fatty acids: The possibility of diet intervention in Parkinson's disease

  2023cites this paper
• Iron accumulation and axonal damage of cerebellum in idiopathic cervical dystonia

  2023cites this paper
• Emotion in Action: When emotions Meet Motor Circuits.

  2023cites this paper
• N-Acetylcysteine Treatment May Compensate Motor Impairments through Dopaminergic Transmission Modulation in a Striatal 6-Hydroxydopamine Parkinson’s Disease Rat Model

  2023cites this paper
• Sleep and circadian rhythms in Parkinson’s disease and preclinical models

  2022cites this paper
• Genetically engineered mesenchymal stem cells with dopamine synthesis for Parkinson’s disease in animal models

  2022cites this paper
• Assessment of the anti-nociceptive effects of fetal ventral mesencephalic tissue allografts in a rat model of hemi-Parkinson’s disease using fMRI

  2022cites this paper
• Neuroprotective effects of insulin-like growth factor-2 in 6-hydroxydopamine-induced cellular and mouse models of Parkinson’s disease

  2022influential citation
• Africanized Bee Venom (Apis mellifera Linnaeus): Neuroprotective Effects in a Parkinson’s Disease Mouse Model Induced by 6-hydroxydopamine

  2022influential citation
• Preclinical Model to Evaluate Outcomes of Amyloid Cross-Toxicity in the Rodent Brain.

  2022cites this paper
• Scorpion venom heat-resistant synthetic peptide protects dopamine neurons against 6-hydroxydopamine neurotoxicity in C. elegans.

  2022cites this paper
• CB2 Agonist GW842166x Protected against 6-OHDA-Induced Anxiogenic- and Depressive-Related Behaviors in Mice

  2022cites this paper
• Better Outcomes with Intranigral versus Intrastriatal Cell Transplantation: Relevance for Parkinson’s Disease

  2022cites this paper
• Inhibition of Vascular Adhesion Protein 1 Protects Dopamine Neurons From the Effects of Acute In�ammation and Restores Habit Learning in the Striatum

  2021cites this paper
• 22(R)-hydroxycholesterol for dopaminergic neuronal specification of MSCs and amelioration of Parkinsonian symptoms in rats

  2021cites this paper
• The Neuroprotective Effects of the CB2 Agonist GW842166x in the 6-OHDA Mouse Model of Parkinson’s Disease

  2021cites this paper
• Unilateral Intrastriatal 6-Hydroxydopamine Lesion in Mice: A Closer Look into Non-Motor Phenotype and Glial Response

  2021influential citation
• Application of neurotoxin- and pesticide-induced animal models of Parkinson’s disease in the evaluation of new drug delivery systems

  2021cites this paper
• Glutamatergic Neurons in the Caudal Zona Incerta Regulate Parkinsonian Motor Symptoms in Mice

  2021cites this paper
• Inhibition of vascular adhesion protein 1 protects dopamine neurons from the effects of acute inflammation and restores habit learning in the striatum

  2021cites this paper
• Improving Well-Being and Survival in the 6-OHDA Lesion Model of Parkinson´s Disease in Mice: Step-By-Step Protocol

  2021cites this paper
• Scorpion venom heat‐resistant synthesized peptide ameliorates 6‐OHDA‐induced neurotoxicity and neuroinflammation: likely role of Nav1.6 inhibition in microglia

  2021cites this paper
• Neurotoxin-Induced Rodent Models of Parkinson’s Disease: Benefits and Drawbacks

  2021cites this paper
• Analysis of the Neuroproteome Associated With Cell Therapy After Intranigral Grafting in a Mouse Model of Parkinson Disease

  2021cites this paper
• Dopaminergic Progenitors Derived From Epiblast Stem Cells Function Similarly to Primary VM-Derived Progenitors When Transplanted Into a Parkinson’s Disease Model

  2020influential citation
• Video-based assessments of the hind limb stepping in a mouse model of hemi-parkinsonism.

  2020cites this paper
• Direct-Pathway Spiny Projection Neuron Inhibition Evokes Transient Circuit Imbalance Manifested as Rotational Behavior.

  2020cites this paper
• Erythropoietin modulates antioxidant signalling.

  2020cites this paper
• Pre-proof Erythropoietin modulates antioxidant signalling

  2020cites this paper
• Impact of Aging on the 6-OHDA-Induced Rat Model of Parkinson’s Disease

  2020cites this paper
• Glia-to-Neuron Conversion by CRISPR-CasRx Alleviates Symptoms of Neurological Disease in Mice.

  2020cites this paper
• Back and to the Future: From Neurotoxin‐Induced to Human Parkinson's Disease Models

  2020cites this paper
• Comparison of Actions between L-DOPA and Different Dopamine Agonists in Striatal DA-Depleted Microcircuits In Vitro: Pre-Clinical Insights.

  2019cites this paper
• Chemogenetic Targeting of Dorsomedial Direct-pathway Striatal Projection Neurons Selectively Elicits Rotational Behavior in Mice.

  2019cites this paper
• The Amphetamine Induced Rotation Test: A Re-Assessment of Its Use as a Tool to Monitor Motor Impairment and Functional Recovery in Rodent Models of Parkinson’s Disease

  2019cites this paper
• Functional Alteration of Cerebello–Cerebral Coupling in an Experimental Mouse Model of Parkinson’s Disease

  2019cites this paper
• Implementation of improved postoperative care decreases the mortalit1y rate of operated mice after an abundant 6-hydroxy dopamine lesion of nigrostriatal dopaminergic neurons

  2019cites this paper
• mGluR5 Allosteric Modulation Promotes Neurorecovery in a 6-OHDA-Toxicant Model of Parkinson’s Disease

  2019cites this paper
• Chondroitinase ABC reduces dopaminergic nigral cell death and striatal terminal loss in a 6-hydroxydopamine partial lesion mouse model of Parkinson’s disease

  2019cites this paper
• Erythropoietin as a Modulator of Pathology in a Toxicant Mouse Model of Parkinson’s Disease

  2019cites this paper
• Excess amounts of 3‐iodo‐l‐tyrosine induce Parkinson‐like features in experimental approaches of Parkinsonism

  2018cites this paper
• Neuronal activity pattern defects in the striatum in awake mouse model of Parkinson’s disease

  2018cites this paper
• Unilateral Botulinum Neurotoxin-A Injection into the Striatum of C57BL/6 Mice Leads to a Different Motor Behavior Compared with Rats

  2018cites this paper
• Inflammasome inhibition prevents α-synuclein pathology and dopaminergic neurodegeneration in mice

  2018cites this paper
• A chemogenetic approach for treating experimental Parkinson's disease

  2018cites this paper
• Neuroprotection against 6-OHDA toxicity in PC12 cells and mice through the Nrf2 pathway by a sesquiterpenoid from Tussilago farfara

  2018cites this paper
• Intrastriatal administration of botulinum neurotoxin A normalizes striatal D2R binding and reduces striatal D1R binding in male hemiparkinsonian rats

  2018cites this paper
• Analysis of respiratory movements in a mouse model of late Parkinson's disease submitted to stress.

  2018cites this paper
• El modelo de 6-hidroxidopamina y la fisiopatología parkinsoniana: nuevos hallazgos en un viejo modelo

  2017cites this paper
• Animal Model of Parkinson Disease: Neuroinflammation and Apoptosis in the 6-Hydroxydopamine-Induced Model

  2017cites this paper
• The 6-hydroxydopamine model and parkinsonian pathophysiology: Novel findings in an older model.

  2017cites this paper
• Impact of the Chronic Omega‐3 Fatty Acids Supplementation in Hemiparkinsonism Model Induced by 6‐Hydroxydopamine in Rats

  2017cites this paper
• Investigating chondroitin sulphate proteoglycans as a therapeutic target for Parkinson's disease

  2017cites this paper
• Down‐regulation of dorsal striatal &agr;CaMKII causes striatum‐related cognitive and synaptic disorders

  2017cites this paper
• Functional single-walled carbon nanotubes 'CAR' for targeting dopamine delivery into the brain of parkinsonian mice.

  2017cites this paper
• A translational approach to capture gait signatures of neurological disorders in mice and humans

  2017cites this paper
• Involvement of BDNF/TrkB signaling in the effect of diphenyl diselenide on motor function in a Parkinson's disease rat model

  2017cites this paper
• Distinct alterations in motor & reward seeking behavior are dependent on the gestational age of exposure to LPS-induced maternal immune activation.

  2017cites this paper
• Post 6-OHDA lesion exposure to stress affects neurotrophic factor expression and aggravates motor impairment

  2017cites this paper
• Implications of Circadian Rhythm in Dopamine and Mood Regulation

  2017cites this paper
• Acetyl-l-Carnitine via Upegulating Dopamine D1 Receptor and Attenuating Microglial Activation Prevents Neuronal Loss and Improves Memory Functions in Parkinsonian Rats

  2016cites this paper
• L-DOPA Reverses the Increased Free Amino Acids Tissue Levels Induced by Dopamine Depletion and Rises GABA and Tyrosine in the Striatum

  2016cites this paper
• hESC-derived neural progenitors prevent xenograft rejection through neonatal desensitisation

  2016cites this paper
• Npas1+ Pallidal Neurons Target Striatal Projection Neurons

  2016cites this paper
• Chemical Control of Grafted Human PSC-Derived Neurons in a Mouse Model of Parkinson's Disease.

  2016cites this paper
• Heterotopic Mucosal Grafting Enables the Delivery of Therapeutic Neuropeptides Across the Blood Brain Barrier.

  2016cites this paper
• How compensation breaks down in Parkinson's disease: Insights from modeling of denervated striatum

  2016cites this paper
• Investigating the developmental and behavioral consequences of maternal immune activation on affected offspring

  2015cites this paper
• GDNF is not required for catecholaminergic neuron survival in vivo

  2015cites this paper
• The 6-OHDA mouse model of Parkinson's disease - Terminal striatal lesions provide a superior measure of neuronal loss and replacement than median forebrain bundle lesions.

  2015cites this paper
• Long-term treatment with L-DOPA or pramipexole affects adult neurogenesis and corresponding non-motor behavior in a mouse model of Parkinson's disease.

  2015cites this paper
• Loss of glutamic acid decarboxylase (Gad67) in striatal neurons expressing the Drdr1a dopamine receptor prevents L-DOPA-induced dyskinesia in 6-hydroxydopamine-lesioned mice.

  2015cites this paper
• Valproic Acid Neuroprotection in the 6-OHDA Model of Parkinson's Disease Is Possibly Related to Its Anti-Inflammatory and HDAC Inhibitory Properties

  2015cites this paper
• A partial lesion model of Parkinson's disease in mice--characterization of a 6-OHDA-induced medial forebrain bundle lesion.

  2015influential citation
• Cineradiographic analysis of respiratory movements in a mouse model for early Parkinson's disease.

  2015cites this paper
• Chapter 8 – Techniques for Motor Assessment in Rodents

  2015cites this paper
• Cerebral dopamine neurotrophic factor (CDNF) and Parkinson’s disease: Behavioural and clinical investigations

  2014cites this paper
• Neuroprotective effect of Tinospora cordifolia ethanol extract on 6-hydroxy dopamine induced Parkinsonism

  2014cites this paper
• Transcription factors Foxa1 and Foxa2 are required for adult dopamine neurons maintenance

  2014cites this paper
• Les systèmes monoaminergiques : implication dans la physiopathologie et la thérapie de la maladie de Parkinson

  2014cites this paper
• Time course of dopamine neuron loss and glial response in the 6‐OHDA striatal mouse model of Parkinson's disease

  2014cites this paper
• Comparison of 6‐hydroxydopamine lesions of the substantia nigra and the medial forebrain bundle on a lateralised choice reaction time task in mice

  2013cites this paper
• Therapeutic effects of repetitive transcranial magnetic stimulation in an animal model of Parkinson's disease.

  2013cites this paper
• Altered biometal homeostasis is associated with CLN6 mRNA loss in mouse neuronal ceroid lipofuscinosis

  2013cites this paper
• l-DOPA and graft-induced dyskinesia: Different treatment, same story?

  2013cites this paper
• Behavioural recovery on simple and complex tasks by means of cell replacement therapy in unilateral 6‐hydroxydopamine‐lesioned mice

  2013cites this paper
• Tissue Engineering and Regenerative Medicine Enhancement of Polysialic Acid Expression Improves Function of Embryonic Stem-Derived Dopamine Neuron Grafts in Parkinsonian Mice

  2013cites this paper